308430.KQ CellBion Co., Ltd.

Healthcare Biotechnology KOSDAQ
11,670 KRW
Close of Oct 31, 2026
9,930 42,200
Market cap
KRW 151B
P/E
21.2x
P/B
4.17x
ROE
66.5%
Dividend yield
-
Fundamental score
1.8/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 308430.KQ undervalued?

Graham number
Price11,670
Graham value5,891
Premium98.1%

308430.KQ trades 98.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CellBion Co., Ltd. fundamental analysis

8 of 22 checks passed

ROE 2/2

High return on equity (66.5%), above 20%.

ROA 1/1

Return on assets (28.8%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-4.0%) is below the industry median (4.8%).

Revenue Growth 1/2

Revenue grew 3.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (17.7%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 23.0x against interest expense, well covered.

PE vs Market 0/1

PE (21.2x) is above the market median (11.3x).

PE vs Industry 1/1

PE (21.2x) is below the industry median (28.9x).

PBV 0/1

Price to book (4.2x) is above the industry median (2.4x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 88.3, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

CellBion Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CellBion Co., Ltd.

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, curre…

Full company profile